Drug intelligence / Profile preview

IB003 (Interactome Biotherapeutics)

Development stage: Preclinical
Lead developer: Interactome Biotherapeutics
Modality: Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

IB003 is an early-stage therapeutic candidate being developed by Interactome Biotherapeutics for neuroimmunological indications. It utilizes a dual-modality approach, combining gene therapy with small extracellular vesicles (sEVs or exosomes) as a delivery platform. The program leverages the company's proprietary Native Nano Platform, which uses exosomes as natural drug delivery vehicles to transport therapeutic genetic cargo to target cells. This approach aims to modulate inflammation and promote cellular regeneration within the nervous system.

Beyond the preview

Go deeper on IB003 (Interactome Biotherapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IB003 (Interactome Biotherapeutics).

Explore the full profile